Ginkgo Bioworks

Historical price data

Ginkgo Bioworks is on a mission to make biology easier to engineer by automating the manual benchwork that bottlenecks biotechnology. Founded in 2008 by a team of MIT scientists, the company has developed a comprehensive platform of autonomous labs and software that allows customers to design and run biological experiments at scale. As a publicly traded company, Ginkgo aims to democratize access to advanced bioengineering capabilities, empowering scientists to focus on creativity and insight rather than repetitive tasks.

An integrated platform of autonomous labs, robotics, and AI software that enables scientists to design and run biological experiments at scale, programmatically.

Total raised: $2.4B

Ginkgo competes with traditional CROs, specialized cloud/automation labs (e.g., Strateos, Emerald Cloud Lab), and internal efforts by large biopharma companies. Its differentiation lies in its end-to-end integrated platform, scale of operations, and broad horizontal applicability across industries.